Oncology Institute Inc (NASDAQ: TOI) has experienced a rise in its stock price by 18.67 compared to its previous closing price of 0.31. However, the company has seen a gain of 17.28% in its stock price over the last five trading days. globenewswire.com reported 2024-12-18 that New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care
Is It Worth Investing in Oncology Institute Inc (NASDAQ: TOI) Right Now?
The 36-month beta value for TOI is also noteworthy at 0.13. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TOI is 36.80M, and at present, short sellers hold a 0.88% of that float. The average trading volume of TOI on January 15, 2025 was 1.83M shares.
TOI’s Market Performance
The stock of Oncology Institute Inc (TOI) has seen a 17.28% increase in the past week, with a 68.14% rise in the past month, and a 17.09% gain in the past quarter. The volatility ratio for the week is 17.89%, and the volatility levels for the past 30 days are at 18.17% for TOI. The simple moving average for the past 20 days is 37.38% for TOI’s stock, with a -26.74% simple moving average for the past 200 days.
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with Jefferies repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to Jefferies is $2.50 based on the research report published on February 26, 2024 of the previous year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see TOI reach a price target of $7. The rating they have provided for TOI stocks is “Buy” according to the report published on September 14th, 2022.
Jefferies gave a rating of “Buy” to TOI, setting the target price at $10 in the report published on August 15th of the previous year.
TOI Trading at 55.29% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.90% of loss for the given period.
Volatility was left at 18.17%, however, over the last 30 days, the volatility rate increased by 17.89%, as shares surge +60.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.46% upper at present.
During the last 5 trading sessions, TOI rose by +17.31%, which changed the moving average for the period of 200-days by -79.89% in comparison to the 20-day moving average, which settled at $0.2693. In addition, Oncology Institute Inc saw 19.71% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TOI starting from Hively Brad, who purchase 250,000 shares at the price of $0.17 back on Nov 26 ’24. After this action, Hively Brad now owns 616,753 shares of Oncology Institute Inc, valued at $42,500 using the latest closing price.
Hively Brad, the Director of Oncology Institute Inc, purchase 50,000 shares at $0.15 during a trade that took place back on Dec 02 ’24, which means that Hively Brad is holding 666,753 shares at $7,500 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.13 for the gross margin
The net margin for Oncology Institute Inc stands at -0.17. The total capital return value is set at -0.48. Equity return is now at value -131.66, with -28.92 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 0.89 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 7.94. The interest coverage ratio of the stock is -7.68.
Currently, EBITDA for the company is -70.45 million with net debt to EBITDA at -1.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.27. The receivables turnover for the company is 6.91for trailing twelve months and the total asset turnover is 2.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
In summary, Oncology Institute Inc (TOI) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
